

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
May 21, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

May 21, 2007  
Date of Report (Date of earliest event reported)

ANTIGENICS INC.

-----  
(Exact name of registrant as specified in its charter)  
-----

-----  
DELAWARE                                      000-29089                                      06-1562417  
(State or other jurisdiction                      (Commission                                      (IRS Employer  
of incorporation)                                      File Number)                                      Identification No.)  
-----

162 Fifth Avenue, Suite 900  
New York, NY                                      10010  
(Address of principal executive offices)                                      (Zip Code)

212-994-8200  
(Registrant's telephone number, including area code)  
-----

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On May 21, 2007, Antigenics Inc. announced additional follow-up data on the company's Oncophage(R) (vitespen), a Phase 3 investigational therapeutic cancer vaccine. The end-of-study results, which reflect an additional 17 months' data collection, showed that in a substantial subset of patients (n = 362) at intermediate risk for disease

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival (RFS) of approximately 45 percent (P <0.01; hazard ratio [HR] = 0.55). The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated May 21, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: May 21, 2007

By: /s/ Garo H. Armen  
-----  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
-----	-----
99.1	Press Release dated May 21, 2007